193 Results
Sort By:
Published on February 16, 2022
A team at the University of Nevada reports the first successful CRISPR-Cas9 genome editing in the black-legged tick, something the researchers hope will help control the insect and slow or stop the spread of tick borne diseases such as Lyme disease. Despite their capacity to spread debilitating pathogens, research on…
Published on November 12, 2021
Highlighting the need to monitor patients who have undergone CRISPR-Cas9-based gene therapy for cancer-related mutations, researchers at Sanford Burnham Prebys have shown that gene editing, specifically gene knockout (KO) using CRISPR-Cas9 technology, can favor cells with mutated forms of p53 or KRAS genes linked to cancer. “Our study shows that…
Published on December 23, 2019
Don’t trust. Just verify. That could be the motto of the Cancer Dependency Map, a project to pinpoint the genes that are critical for the survival of cancer cells. Such genes have been cataloged in various datasets. But whether the datasets match each other hasn’t always been clear. Encouragingly, two…
Published on September 19, 2019
The British sequencing company famous for producing ultra-long reads, Oxford Nanopore Technologies announced today that have entered into a non-exclusive license agreement with Caribou Biosciences for CRISPR-Cas9 enrichment for nanopore sequencing. Caribou has granted Oxford Nanopore a worldwide, non-exclusive license under foundational CRISPR-Cas9 intellectual property controlled by Caribou for nanopore…
Published on June 26, 2019
The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) has touched off another round in the long and bitter legal wrangle over who invented CRISPR gene-editing technology by signaling it will consider the invention of CRISPR-Cas9 in eukaryotic cells. The PTAB has declared a…
Published on June 13, 2019
Researchers headed by teams at the Chinese Academy of Sciences, and Massachusetts Institute of Technology (MIT), have used CRISPR-Cas9 gene editing to engineer macaque monkeys with germline-transmissible mutations in Shank3, a gene that is linked with a form of autism and other human neurodevelopmental disorders. The engineered animals demonstrated altered…
Published on September 3, 2018
CRISPR-Cas9 has, for the first time, been tested by systemic delivery in a large animal—and the results are striking. Working in a dog model of Duchenne muscular dystrophy (DMD), the gene editing not only restored the expression of the protein dystrophin, it also improved muscle histology in the dogs. Eric…
Published on July 17, 2018
Scientists at the Wellcome Sanger Institute in the U.K. have reported another potential hurdle for the CRISPR community, publishing findings today that call the precision of CRISPR-Cas9 gene editing into question. While much work has addressed the specificity of CRISPR-Cas9 editing to target the gene of interest and not result…
Published on April 11, 2018
Let’s say you want to learn how a particular DNA sequence variant affects different genes. You could painstakingly introduce the variant, and monitor its effect, gene by gene. How tedious. Alternatively, you could adapt a technique that has been used to assess genetic knockdowns genome wide. This technique is a…
Published on January 22, 2018
A platform for gene delivery and tumor therapy has been introduced that harnesses the power of the CRISPR/Cas9 gene-editing system. At the same time, the platform avoids some of the drawbacks of the CRISPR-Cas9 system. Specifically, the platform can cope with CRISPR-Cas9’s sheer bulk, achieving highly efficient and targeted delivery…
Published on December 12, 2017
Small differences in the genetic codes of individuals could significantly impact the efficacy, side effects and safety of treatments created via CRISPR/Cas9 gene editing according to researchers at Harvard Medical School, Boston Children’s Hospital, and the Université de Montréal. Their findings suggest that a one-size-fits-all approach to therapeutic gene editing…
Published on December 7, 2017
Charles River Laboratories has announced it has arranged a nonexclusive license to ERS Genomics' CRISPR/Cas9 technology, even as a legal battles over rights to the gene-editing technology continue to move through patent governing bodies. Charles River has licensed from ERS Genomics nonexclusive access to ERS’s CRISPR/Cas9 patents, which are based…
Published on November 21, 2017
Researchers at Cardiff University in Wales have used the CRISPR/Cas9 gene editing technology to engineer killer T cells that are up to a thousand times more sensitive to cancer cell antigens than T cells engineered using more conventional approaches, and which allowed far better targeting of T cells to cancer…
Published on November 14, 2017
MIT researchers seeking for ways to avoid the complications associated with CRISPR/Cas9 delivery via viral vectors, have developed a new lipid nanoparticle that features a chemically modified single guide RNA (sgRNA), which may protect it against nuclease degradation, and thereby boost efficiency of the overall CRISPR/Cas9 gene-editing system. According to…
Published on July 20, 2017
A new means of identifying molecular pathways for which combination treatments of checkpoint inhibitors and new drugs could effectively block programmed cell death protein 1 (PD-1) has been demonstrated in a just-published study Researchers based at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that they have used CRISPR/Cas9 genome-editing…